Insight

ASCO 2025 Science in Seconds: Charu Aggarwal on How a Molecular Assay May Help Identify People with NSCLC

Charu Aggarwal/pc3i.upenn.edu

Jun 1, 2025, 07:55

ASCO 2025 Science in Seconds: Charu Aggarwal on How a Molecular Assay May Help Identify People with NSCLC

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“Check out our ASCO 25 Science in Seconds!

Dr. Charu Aggarwal discusses how a molecular assay may help identify people with NSCLC who could benefit from adj. chemotherapy.

Learn more.”

Title: An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay

Journal: ASCO, Journal of Clinical Oncology

Authors: David Spigel, Virginie Westeel, Ian Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Matthew Gubens, John Crowley, Heiko von der Leyen, Gavitt Woodard, Johannes Kratz, David Jablons, Michael Mann

Read the full abstract.

Charu Aggarwal

More posts featuring Charu Aggarwal on OncoDaily.

Adam Bograd American Society of Clinical Oncology ASCO ASCO 2025 Charu Aggarwal Clotilde Deldycke David Jablons David Spigel Firas Badin Florian Guisier Frank Griesinger Gaelle Rousseau-Bussac Gavitt Woodard Heiko von der Leyen Ian Anderson Johannes Kratz John Crowley Laurent Greillier Matthew Gubens Michael Mann molecular assay NSCLC Olivier Bylicki Science in Seconds Virginie Westeel Wangjian Zhong

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care